Hemab Therapeutics

Focus: Hemab Therapeutics is a Denmark-based biotech focused on bleeding disorder treatments, particularly rare hematologic conditions like Von Willebrand Disease and Glanzmann Thrombasthenia. With 5,000+ employees, the company operates at Series C+ stage with an established clinical development footprint.

Hematology

Profile data last refreshed 30m ago · AI intelligence enriched 2mo ago

Funding Stage

SERIES C +

Employees

5000+

Open Jobs

About Hemab Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Hemab Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Comparison of blood samples between the two groups

Leiomyoma, Uterine

N/A

Clinical Trials (1)

NCT05607602Are Uterine Fibroids Pro-thrombotic?

N/A

Help build intelligence for Hemab Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused therapeutic area (hematology/bleeding disorders) offers deep specialization and niche expertise that commands premium market positioning
Series C+ funding stage with 5,000+ employees indicates stability beyond early-stage risk while maintaining growth trajectory
Active clinical pipeline with Phase 1/2 programs (HMB-001, HMB-002, Sutacimig) provides clear catalyst visibility for career advancement and learning

Watch Out For

Only 6 active job openings and hiring concentrated in non-core functions (Clinical Ops, CMC, Finance, Medical Writing) suggests limited headcount expansion and bottleneck for career mobility
Pipeline remains early-stage (no Phase 3 programs) with uncertain probability of success; rare disease focus limits market size and revenue upside compared to larger biotech peers

Generated by Claude from Hemab Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Online Survey

Von Willebrand Diseases

N/A

Clinical Trials (1)

NCT06064643The Lived Experience of People With Von Willebrand Disease

N/A

Clinical outcomes of patients with VWD, Type 1

Von Willebrand Disease (VWD)

N/A

Clinical Trials (1)

NCT06610201A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

N/A

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Hematologic Disorder

N/A

survey and interview

Glanzmann Thrombasthenia

N/A

Clinical Trials (1)

NCT05315232The Experiences of People Who Live With Glanzmanns Thrombasthenia.

N/A

HMB-001

Glanzmann Thrombasthenia

PHASE_1_2

Clinical Trials (1)

NCT06211634A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

Phase 1/2

HMB-002

Von Willebrand Disease (VWD)

PHASE_1_2

Clinical Trials (1)

NCT06754852A Study Assessing HMB-002 in Participants With Von Willebrand Disease

Phase 1/2

Sutacimig

Congenital Factor VII Deficiency

PHASE_2

Clinical Trials (1)

NCT07347249A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency